Copenhagen, Denmark, December 18 2015 – – Vipergen ApS, a biotechnology company focused on small molecule drug discovery using its proprietary 2nd generation DNA-encoded library platform, today announced the signing of a drug discovery agreement with Amgen Inc., a global leader in the biotech industry.
Under the terms of the agreement, Vipergen’s small molecule discovery engine will be applied across therapeutic areas to identify novel hits/leads for selected targets from Amgen. Amgen obtains exclusive options to hits and leads discovered in the course of the collaboration. Other terms of the agreement were not disclosed.
“We are very excited to work with Amgen, recognized as one of the world’s most successful biotech companies,” said Nils Hansen, Chief Executive Officer of Vipergen. “Vipergen’s small molecule discovery engine is designed to deliver high quality hits and leads for very challenging and important protein targets, such as those Amgen is tackling. We look forward to working with the excellent scientific team at Amgen to help transform their important discoveries into novel therapies for patients with serious illnesses.“
About Vipergen ApS
Vipergen is dedicated to small molecule drug discovery using DNA-encoded library platforms.
Vipergen leverages its innovative and proprietary drug discovery platforms in partnerships with leading pharmaceutical and biotech companies.
Vipergen´s two 2nd generation technology platforms – The YoctoReactor® for synthesizing DNAencoded chemical libraries and Binder Trap Enrichment®
for screening of such libraries – are designed to deliver high fidelity drug discovery.
For further details about Vipergen and the YoctoReactor®/ Binder Trap Enrichment® drug discovery technology platforms please visit www.vipergen.com or contact:
Vipergen ApS
Dr. Nils Hansen, Chief Executive Officer
Phone: +45 2523 6680
[email protected]